JP2016074736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016074736A5 JP2016074736A5 JP2016014128A JP2016014128A JP2016074736A5 JP 2016074736 A5 JP2016074736 A5 JP 2016074736A5 JP 2016014128 A JP2016014128 A JP 2016014128A JP 2016014128 A JP2016014128 A JP 2016014128A JP 2016074736 A5 JP2016074736 A5 JP 2016074736A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following structure
- cell
- composition
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108010017842 Telomerase Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000005907 cancer growth Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- HSEMFIZWXHQJAE-UHFFFAOYSA-N Amide-Hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50150903P | 2003-09-09 | 2003-09-09 | |
| US60/501,509 | 2003-09-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010286755A Division JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137263A Division JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016074736A JP2016074736A (ja) | 2016-05-12 |
| JP2016074736A5 true JP2016074736A5 (https=) | 2016-09-01 |
| JP6158966B2 JP6158966B2 (ja) | 2017-07-05 |
Family
ID=34273050
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526347A Expired - Lifetime JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2010286755A Expired - Lifetime JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016014128A Expired - Lifetime JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2018025362A Expired - Lifetime JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2023086871A Withdrawn JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526347A Expired - Lifetime JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2010286755A Expired - Lifetime JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2018025362A Expired - Lifetime JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2023086871A Withdrawn JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US7494982B2 (https=) |
| EP (3) | EP3682903A1 (https=) |
| JP (10) | JP4690324B2 (https=) |
| KR (3) | KR101319388B1 (https=) |
| CN (2) | CN100393209C (https=) |
| AU (2) | AU2004271215B2 (https=) |
| BR (1) | BRPI0414222B8 (https=) |
| CA (1) | CA2536015C (https=) |
| CY (2) | CY1120113T1 (https=) |
| DK (2) | DK3342425T3 (https=) |
| ES (2) | ES2662196T3 (https=) |
| HU (2) | HUE048359T2 (https=) |
| IL (1) | IL173747A (https=) |
| MX (1) | MXPA06002660A (https=) |
| NZ (1) | NZ545516A (https=) |
| PL (2) | PL3342425T3 (https=) |
| PT (2) | PT3342425T (https=) |
| SI (2) | SI1667522T1 (https=) |
| WO (1) | WO2005023994A2 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100393209C (zh) * | 2003-09-09 | 2008-06-11 | 杰龙公司 | 用于端粒酶抑制的改性寡核苷酸 |
| ATE503014T1 (de) * | 2003-11-04 | 2011-04-15 | Geron Corp | Rna-amidate und thioamidateur rnai |
| ME02933B (me) | 2004-07-02 | 2018-04-20 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozionih monomera |
| EP1876893B1 (en) * | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| SI2898887T1 (sl) | 2006-10-30 | 2019-01-31 | Geron Corporation | Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka |
| WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| US8507200B2 (en) | 2007-02-09 | 2013-08-13 | Northwestern University | Particles for detecting intracellular targets |
| US9155753B2 (en) * | 2007-03-09 | 2015-10-13 | Geron Corporation | Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors |
| WO2008141248A2 (en) | 2007-05-10 | 2008-11-20 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for rna synthesis |
| DK2160464T3 (da) | 2007-05-30 | 2014-08-04 | Univ Northwestern | Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser |
| TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
| KR20110025863A (ko) * | 2008-07-02 | 2011-03-11 | 산타리스 팔마 에이/에스 | Ｈｓｐ２７을 표적화하는 ｒｎａ 길항제 |
| EP2175023A1 (en) * | 2008-07-31 | 2010-04-14 | The University of Zurich | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA |
| LT3029154T (lt) | 2008-10-17 | 2017-12-27 | Geron Corporation | Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas |
| CN106955360A (zh) | 2008-11-24 | 2017-07-18 | 西北大学 | 多价rna纳米颗粒组合物 |
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| DK2494075T3 (en) | 2009-10-30 | 2018-07-23 | Univ Northwestern | TABLE-MANAGED NANOCONJUGATES |
| WO2011079290A1 (en) * | 2009-12-24 | 2011-06-30 | Northwestern University | Oligonucleotide specific uptake of nanoconjugates |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| ES2656958T3 (es) | 2011-03-28 | 2018-03-01 | Geron Corporation | Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US9889209B2 (en) | 2011-09-14 | 2018-02-13 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CA2887702C (en) * | 2012-10-26 | 2023-08-01 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| US9228189B2 (en) | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| CA2892445C (en) | 2012-11-30 | 2022-06-28 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| UA128370C2 (uk) | 2012-12-07 | 2024-06-26 | Джерон Корпорейшн | Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм |
| ES3047667T3 (en) | 2013-02-22 | 2025-12-04 | Univ Leland Stanford Junior | Methods relating to telomere extension |
| CN105579582A (zh) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体 |
| JP6794258B2 (ja) | 2013-09-30 | 2020-12-02 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | オリゴヌクレオチドについてのホスホロジアミデート骨格結合 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| KR20170078843A (ko) | 2014-11-21 | 2017-07-07 | 노오쓰웨스턴 유니버시티 | 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수 |
| KR101766373B1 (ko) * | 2015-01-05 | 2017-08-09 | 권영아 | 루테리온을 이용한 암세포의 텔로머라아제 억제방법 |
| AU2016250576C1 (en) | 2015-04-23 | 2021-05-06 | Geron Corporation | Methods of polynucleotide preparation using multivalent cation salt compositions |
| EP3329004B1 (en) | 2015-07-29 | 2020-01-15 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutic oligonucleotides |
| EP3124609A1 (en) * | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| WO2017192679A1 (en) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd. | Methods and compositions of biologically active agents |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| KR102778110B1 (ko) * | 2017-04-20 | 2025-03-10 | 신테나 아게 | 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도 |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| MA49555A (fr) * | 2017-07-10 | 2021-04-28 | Geron Corp | Procédé amélioré de préparation d'imetelstat |
| KR102867725B1 (ko) | 2017-07-28 | 2025-10-13 | 제론 코포레이션 | 골수형성이상 증후군의 치료 방법 |
| WO2019217459A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| UA130012C2 (uk) | 2018-11-29 | 2025-10-15 | Джерон Корпорейшн | Спосіб лікування мієлодиспластичного синдрому |
| US20220370491A1 (en) * | 2019-09-18 | 2022-11-24 | National University Corporation Tokyo Medical And Dental University | Nucleic acid complex |
| AU2020372865A1 (en) * | 2019-10-28 | 2022-05-26 | Geron Corporation | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same |
| CN114901269A (zh) * | 2019-10-28 | 2022-08-12 | 美国杰龙生物医药公司 | 3-棕榈酰基-酰胺基-1,2-丙二醇和3-棕榈酰基-酰胺基-2-羟基-1-二甲氧基三苯基甲基醚-丙烷的结晶固体及其制备和使用方法 |
| JP2023534295A (ja) | 2020-07-17 | 2023-08-08 | ジェロン・コーポレーション | 皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法 |
| CN116917476A (zh) * | 2021-03-03 | 2023-10-20 | 国立大学法人东京大学 | 非环式苏氨醇核酸 |
| EP4316495A4 (en) * | 2021-03-25 | 2025-12-31 | Aptacure Therapeutics Ltd | CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE |
| EP4463151A4 (en) | 2022-01-19 | 2025-10-01 | Univ Northwestern | Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy |
| WO2024257861A1 (ja) * | 2023-06-16 | 2024-12-19 | 日産化学株式会社 | 脂質結合オリゴヌクレオチド又はその複合体 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| EP0462145B1 (en) | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| CA2079109A1 (en) * | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
| US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
| US5419966A (en) * | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US7067497B2 (en) * | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| EP0724589B1 (en) | 1993-10-18 | 2005-12-07 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| HUT76094A (en) | 1994-03-18 | 1997-06-30 | Lynx Therapeutics | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| AU696702B2 (en) | 1994-07-07 | 1998-09-17 | Geron Corporation | Mammalian telomerase |
| JPH10509447A (ja) | 1994-11-07 | 1998-09-14 | ハイブライドン インコーポレイテッド | ３ｈ−１，２−ベンゾジチオール−３−１，１−ジオキシドを用いた▲上３５▼ｓ−標識オリゴヌクレオチドの合成 |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
| US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| AU2445997A (en) * | 1996-04-10 | 1997-10-29 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
| US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
| AU733610B2 (en) | 1996-12-20 | 2001-05-17 | Geron Corporation | Methods for detecting and inhibiting the RNA component of telomerase |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| CN1317291C (zh) | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| CN100393209C (zh) | 2003-09-09 | 2008-06-11 | 杰龙公司 | 用于端粒酶抑制的改性寡核苷酸 |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| ME02933B (me) | 2004-07-02 | 2018-04-20 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozionih monomera |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2007127163A2 (en) | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| SI2898887T1 (sl) | 2006-10-30 | 2019-01-31 | Geron Corporation | Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka |
-
2004
- 2004-09-09 CN CNB2004800259754A patent/CN100393209C/zh not_active Expired - Lifetime
- 2004-09-09 BR BRPI0414222A patent/BRPI0414222B8/pt active IP Right Grant
- 2004-09-09 SI SI200432432T patent/SI1667522T1/en unknown
- 2004-09-09 EP EP19209408.4A patent/EP3682903A1/en active Pending
- 2004-09-09 KR KR1020117017803A patent/KR101319388B1/ko not_active Expired - Lifetime
- 2004-09-09 MX MXPA06002660A patent/MXPA06002660A/es active IP Right Grant
- 2004-09-09 DK DK17200625.6T patent/DK3342425T3/da active
- 2004-09-09 DK DK04783801.6T patent/DK1667522T3/en active
- 2004-09-09 ES ES04783801.6T patent/ES2662196T3/es not_active Expired - Lifetime
- 2004-09-09 KR KR1020137007201A patent/KR101298493B1/ko not_active Expired - Lifetime
- 2004-09-09 AU AU2004271215A patent/AU2004271215B2/en not_active Expired
- 2004-09-09 PL PL17200625T patent/PL3342425T3/pl unknown
- 2004-09-09 CA CA2536015A patent/CA2536015C/en not_active Expired - Lifetime
- 2004-09-09 WO PCT/US2004/029718 patent/WO2005023994A2/en not_active Ceased
- 2004-09-09 PT PT172006256T patent/PT3342425T/pt unknown
- 2004-09-09 PL PL04783801T patent/PL1667522T3/pl unknown
- 2004-09-09 KR KR1020067004864A patent/KR20060132802A/ko not_active Ceased
- 2004-09-09 US US10/938,184 patent/US7494982B2/en not_active Expired - Lifetime
- 2004-09-09 HU HUE17200625A patent/HUE048359T2/hu unknown
- 2004-09-09 PT PT4783801T patent/PT1667522T/pt unknown
- 2004-09-09 EP EP04783801.6A patent/EP1667522B1/en not_active Expired - Lifetime
- 2004-09-09 NZ NZ545516A patent/NZ545516A/en not_active IP Right Cessation
- 2004-09-09 JP JP2006526347A patent/JP4690324B2/ja not_active Expired - Lifetime
- 2004-09-09 SI SI200432487T patent/SI3342425T1/sl unknown
- 2004-09-09 CN CN200810098490.8A patent/CN101293908B/zh not_active Expired - Lifetime
- 2004-09-09 EP EP17200625.6A patent/EP3342425B1/en not_active Expired - Lifetime
- 2004-09-09 ES ES17200625T patent/ES2775525T3/es not_active Expired - Lifetime
- 2004-09-09 HU HUE04783801A patent/HUE036593T2/hu unknown
-
2006
- 2006-02-15 IL IL173747A patent/IL173747A/en active IP Right Grant
-
2008
- 2008-11-21 US US12/276,127 patent/US20090286853A1/en not_active Abandoned
-
2009
- 2009-10-07 AU AU2009222616A patent/AU2009222616A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/886,080 patent/US20120129918A1/en not_active Abandoned
- 2010-12-22 JP JP2010286755A patent/JP5923241B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-15 JP JP2011274595A patent/JP2012085648A/ja active Pending
-
2012
- 2012-08-21 US US13/590,511 patent/US9404112B2/en not_active Expired - Lifetime
-
2014
- 2014-04-21 JP JP2014087190A patent/JP2014158490A/ja active Pending
-
2015
- 2015-05-18 US US14/714,732 patent/US9657296B2/en not_active Expired - Lifetime
- 2015-05-22 US US14/720,466 patent/US9388415B2/en not_active Expired - Lifetime
- 2015-05-22 US US14/720,467 patent/US9388416B2/en not_active Expired - Lifetime
-
2016
- 2016-01-28 JP JP2016014128A patent/JP6158966B2/ja not_active Expired - Lifetime
- 2016-06-27 US US15/194,230 patent/US10196641B2/en not_active Expired - Lifetime
- 2016-07-12 JP JP2016137263A patent/JP2016214248A/ja not_active Withdrawn
-
2018
- 2018-02-15 JP JP2018025362A patent/JP6758335B2/ja not_active Expired - Lifetime
- 2018-04-03 CY CY20181100365T patent/CY1120113T1/el unknown
-
2019
- 2019-07-17 JP JP2019131757A patent/JP2019170400A/ja not_active Withdrawn
-
2020
- 2020-02-26 CY CY20201100179T patent/CY1122704T1/el unknown
-
2021
- 2021-07-02 JP JP2021110558A patent/JP2021169466A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086871A patent/JP2023099808A/ja not_active Withdrawn